Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, А. Л. Акопов, Alex Martínez‐Martí, Hirotsugu Kenmotsu, Yuh‐Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark L. McCleland, Elizabeth Bennett, Barbara J. Gitlitz, Heather A. Wakelee
Topics & Concepts
AtezolizumabMedicineAdjuvantOncologyAdjuvant chemotherapyStage (stratigraphy)Lung cancerInternal medicineChemotherapyOpen labelCancerClinical trialImmunotherapyBreast cancerPembrolizumabPaleontologyBiologyLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations